Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder
Advances in Clinical and Experimental Medicine · 2022
DOI: 10.17219/acem/155802 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Advances in Clinical and Experimental Medicine, 2022. Verfasst von Xiaojing Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Shandong Mental Health Center, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Schizophrenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
BACKGROUND: Norepinephrine transporter inhibitors that can alter the level of neurotransmitter in the brain are used to treat neurological disorders. However, a number of studies have reported their limited significance as a result of their slow onset of action and moderate efficacy. OBJECTIVES: To determine the effects of norepinephrine reuptake inhibitors (NRIs), reboxetine and atomoxetine on schizophrenia and attention deficit hyperactivity disorder (ADHD). MATERIAL AND METHODS: Relevant articles published between 2000 and 2022 were searched in the MEDLINE, CINAHL (via Ebsco), Web of Science and Scopus databases. Among the various NRIs, studies concerning the 2 potent drugs - reboxetine and atomoxetine - were selected for analysis. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated, along with the exploration of heterogeneity and publication bias, using RevMan software. RESULTS: A total of 14 eligible studies with a combined sample size of 970 patients were included. Using a random effects model, an OR of 0.55 (0.32-0.94), a Tau2 value of 0.23, a ÷2 value of 12.31, 8 degrees of freedom (df), an I2 of 35%, a Z value of 2.19, and a p-value of 0.03 were recorded for reboxetine. Atomoxetine had an OR of 0.35 (0.13-0.97), a Tau2 value of 0.58, a ÷2 value of 7.31, 4 df, an I2 of 45%, a Z value of 1.53, and a p-value of 0.04. All results were statistically significant with a low risk of publication bias, as was evident from the p-values >0.05 derived from the Egger's test and the Begg's test. These drugs provided comparable changes to control drugs in Hamilton Depression Rating Scale (HAM-D) scores, Positive and Negative Syndrome Scale (PANSS) scores and ADHD ratings. This confirms the efficacy of reboxetine for the treatment of schizophrenia and atomoxetine for the treatment of ADHD. CONCLUSION: The present meta-analysis suggests that NRIs are efficacious and therefore they are potential candidate drugs for the treatment of schizophrenia and ADHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Shandong Mental Health Center, Shandong University, Jinan, China.
- Department of Psychology, Taian Traditional Chinese Medicine Hospital, China.
Zitieren
APA
Hu, X., Pan, L., & Li, W. (2022). Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/155802
Vancouver
Hu X, Pan L, Li W. Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder. Advances in Clinical and Experimental Medicine. 2022. doi:10.17219/acem/155802
BibTeX
@article{Hu2022,
author = {Hu, Xiaojing and Pan, Lili and Li, Wenjie},
title = {Meta-analysis on the efficacy of the norepinephrine reuptake inhibitors reboxetine and atomoxetine for the treatment of schizophrenia and attention deficit hyperactivity disorder},
journal = {Advances in Clinical and Experimental Medicine},
year = {2022},
doi = {10.17219/acem/155802}
}
EUVIMED